Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ObiVas
ISRCTN13069630Phase 2Completed
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) comparing Obinutuzumab plus prednisolone with Rituximab plus prednisolone (2 arms). Primary endpoint: Relative percentage change in live single nasal CD19+ B cells in the nasal lymphoid compartment. Started Jan 2023; status: completed.
02
Drugs
obinutuzumabrituximabprednisolone
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on ISRCTN13069630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13069630.